The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wicks, Paul, Rasouliyan, Lawrence, Katic, Bo, Nafees, Beenish, Flood, Emuella, Sasané, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/
https://www.ncbi.nlm.nih.gov/pubmed/27604188
http://dx.doi.org/10.1186/s13104-016-2243-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/
https://www.ncbi.nlm.nih.gov/pubmed/27604188
http://dx.doi.org/10.1186/s13104-016-2243-8

Ejemplares similares